Regeneron shares rose 13.3% after the company reported 36% revenue growth and 70% non-GAAP EPS growth year over year, alongside record sales for Dupixent, EYLEA HD and Libtayo. The call also highlighted potential pipeline catalysts, though the excerpt provides no financial outlook or consensus comparisons to assess.
- Total revenue grew 36% and non-GAAP EPS rose 70% versus the third quarter of 2025, according to management.
- Dupixent global sales reached $6.5 billion, up 35% at constant currency; U.S. sales were $5 billion, up 40%, with growth attributed to demand and gross-to-net favorability.
- U.S. EYLEA HD sales increased 62% to approximately $700 million, nearly two-thirds of the U.S. retinal franchise; physician unit demand rose 20% sequentially.
- Libtayo global sales rose 51% at constant currency to a record $550 million, with U.S. sales up 81% to nearly $400 million.
- Pipeline milestones include an expected November FDA decision on cemdisiran for generalized myasthenia gravis and planned initiation next year of a potentially pivotal POTS study, pending regulatory feedback.
Community Discussion